Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ASND · as of Jun 8, 2026
Key Statistics
Explore Ascendis Pharma A/S Data
asnd stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 25 · Buy rate: 92.0%
The ASND analyst consensus is Buy, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month price target is $287.50, representing +36.61% upside from the current price of $210.45.
Competitors & Peers
asnd competitorsASND
BBIO
BMRN
EXEL
GH
IONSStock Performance
Full HistoryAbout Ascendis Pharma A/S
Ascendis Pharma A/S a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It…
what is ascendis pharma a/s · asnd stock overview · ascendis pharma a/s company profile · who is ascendis pharma a/s ceo · asnd NASDAQ · ascendis pharma a/s headquarters · ascendis pharma a/s business segments
About Stock Overview & Key Data
Ascendis Pharma A/S (ASND) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 28, 2015. As of the latest trading session, ASND stock price is $210.45, with a market capitalization of $13.0B. The stock has returned +21.54% over the past 12 months and -1.31% year-to-date.
According to 25 Wall Street analysts, the consensus rating for Ascendis Pharma A/S stock is Buy, with an average 12-month price target of $287.50. In fiscal year 2025, Ascendis Pharma A/S reported revenue of $691.7M and net income of -$219.0M. For detailed data — including Ascendis Pharma A/S revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Ascendis Pharma A/S (ASND) stock price is $210.45. The stock is traded on NASDAQ under the ticker symbol ASND. The 52-week range is $160.86 – $250.74.